Skip to main content

MODULACION DE LA INMUNIDAD INNATA TEMPRANA POR POXVIRUS

PID2021-128580OB-I00

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Call year 2021
State Plan 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Pathogenesis of the circulating mpox virus and its adaptation to humans

  • Alcamí, Antonio
The recent mpox (monkeypox) outbreak has caused >86,000 infections and 96 deaths (https://ourworldindata.org/monkeypox) and was declared a global health emergency by the WHO (1, 2). The disease is caused by mpox virus (MPXV), a virus endemic in an animal reservoir in the sub-Saharan Africa (Fig. 1). MPXV transmits occasionally to humans, and it spread in a few occasions outside the African continent, causing limited outbreaks. The recent 2022 international outbreak has caused an unprecedented transmission of the virus mainly in men that have sex with men. The extent of the outbreak has decreased dramatically after a few months, with 13 to 37 daily cases worldwide in February 2023. We still do not understand the reasons why the MPXV clade circulating in 2022 was so transmissible in humans. In PNAS, Americo et al. (3) report that the MPXV clade causing the 2022 international outbreak is less virulent in a mouse model than the MPXV clades previously identified and suggest that the virus may be adapting to other species., The author’s research is supported by the Spanish Ministry of Science and Innovation and European Union (European Regional Development’s Funds) (grant PID2021-128580OB-I00), Nextgeneration European Union (EU), and Consejo Superior de Investigaciones Científicas (Plataforma Temática Interdisciplinar Salud Global)
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Poxvirus Immune Evasion

  • Hernáez, Bruno
  • Alcamí, Antonio
Poxviruses have evolved a wide array of mechanisms to evade the immune response, and we provide an overview of the different immunomodulatory strategies. Poxviruses prevent the recognition of viral DNA that triggers the immune responses and inhibit signaling pathways within the infected cell. A unique feature of poxviruses is the production of secreted proteins that mimic cytokines and cytokine receptors, acting as decoy receptors to neutralize the activity of cytokines and chemokines. The capacity of these proteins to evade cellular immune responses by inhibiting cytokine activation is complemented by poxviruses' strategies to block natural killer cells and cytotoxic T cells, often through interfering with antigen presentation pathways. Mechanisms that target complement activation are also encoded by poxviruses. Virus-encoded proteins that target immune molecules and pathways play a major role in immune modulation, and their contribution to viral pathogenesis, facilitating virus replication or preventing immunopathology, is discussed., The authors’ research is supported by the Spanish Ministry of Science and Innovation, the European Union (European Regional Development’s Funds, FEDER) (grants PID2021- 128580OB-I00, PCD2022-133701-I00, and PID2022-136867NB-I00), Nextgeneration EU, and Consejo Superior de Investigaciones Científicas (PTI Salud Global). The authors apologize to those whose work could not be cited owing to space limitations., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

NRF2 controls a diverse network of antiviral effectors with p62 acting as a central restriction factor effective across virus families

  • Pedersen, A.
  • Blay-Cadanet, J.
  • Storgaard, J.
  • Hernáez, Bruno
  • Thyrsted, Jacob
  • Bach-Nielsen, C. S.
  • Twayana, K.
  • Jørgensen, Sofie E.
  • Rio-Bergé, C.
  • Poulsen, C.
  • Thielke, Anne L.
  • Thomsen, E.A.
  • Kalucka, J.
  • Olagnier, David
  • Luo, Yonglun
  • Reggiori, F.
  • Mogensen, Trine
  • Alcamí, Antonio
  • Hansen, Anne Louise
  • Holm, Christian
The transcription factor erythroid 2 (NFE2)-related factor 2 (NRF2) is a key regulator of cellular homeostasis. Recent discoveries have identified agonists of NRF2 as inducers of broad cellular resistance to viral infection including SARS-CoV-2. Nevertheless, it is still unclear to what extent NRF2 itself is an inducer of anti-viral immunity and its downstream antiviral effectors have not been mapped. Here, we first demonstrate through specific genetic activation and silencing that NRF2 restricts SARS-CoV-2 replication. We then used a focused CRISPR-activation screen to map antiviral NRF2-inducible effector genes that restrict replication of SARS-CoV-2, Influenza A virus (IAV), Herpes Simplex virus 1 (HSV1) and Vaccinia virus (VACV). This approach allowed us to identify a range of antiviral effectors each of which restrict members of one or more virus families. Importantly, we identified the NRF2-inducible selective autophagy receptor p62/SQSTM1 as a broadly effective restriction factor across all the tested viruses. Importantly, p62 inhibited SARS-CoV-2 replication in cells treated with the lysosomal inhibitor bafilomycin A1, as well as in cells deficient in the autophagy protein ATG5. Similarly, p62 inhibited replication of HSV1 and IAV independently of ATG5 and ATG16L1 respectively. Thus, NRF2 restricts viral replication through a hitherto underappreciated network of antiviral restriction factors effective across multiple virus families. Importantly, we identify p62 as a broadly acting antiviral effector that restricts viral replication independently of canonical autophagy., This work was supported by Novo Nordisk Foundation through a Hallas-Møller Ascending Investigator Grant (NNF21OC0066798) and a Novo Nordisk project grant in Bioscience and Basic Biomedicine (NNF20OC0064589), by the Hørslev Foundation, by the Beckett Foundation, and by Independent Research Fund Denmark (9030-00078B). Work in the laboratory of A.A. was funded by the Spanish Ministry of Science and Innovation and European Union (European Regional Development's Funds, FEDER) grant PID2021-128580OB-I00. THM was supported by NNF Clinical Distinguished Investigator grant (NNF21OC0067157) and EU Horizon Europe; HORIZON-HLTH-2021-DISEASE-04 (101057100-UNDINE). F.R. is supported by Novo Nordisk Foundation (0066384) and Lundbeck Foundation (R383-2022-180) grants., Peer reviewed